Multiple Myeloma Minimum Residual Disease by Flow Cytometry
Also known as: MM MRD
Use
The Multiple Myeloma Minimum Residual Disease by Flow Cytometry test utilizes a limited phenotyping panel to enumerate and characterize plasma cells in patients with a previously established diagnosis of plasma cell dyscrasia. The test is intended to detect minimal residual disease in clinical settings, providing critical information for the management and treatment of multiple myeloma.
Special Instructions
This test is not New York state approved. Due to short specimen stability, it is recommended that this test be submitted directly to a New York state-approved laboratory. Do not submit sample to ARUP.
Limitations
The assay is developed and its performance characteristics determined by ARUP Laboratories, but it is not cleared or approved by the US Food and Drug Administration. Results are most accurate when linked with morphology and immunohistochemistry of the core biopsy to determine the true disease burden. Flow cytometry may underestimate the plasma cell fraction.
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
LOINC Codes
- 48767-8
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
5 mL
Minimum Volume
1 mL
Container
green (sodium heparin) or lavender (EDTA)
Storage Instructions
Specimen should be received within 24 hours of collection for optimal cell viability.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 48 hours |
| Frozen | Unacceptable |